AI Biomed PredictionsAVIR – Phase 3 HCV data could decide Atea’s next rerating ScanScor Admin / May 20, 2026
AI Biomed PredictionsLXEO – Lexeo Nears Pivotal FDA Decision That Could Reprice Shares ScanScor Admin / May 20, 2026
AI Biomed PredictionsIRD – June science forum may reset Opus Genetics breakout narrative ScanScor Admin / May 20, 2026
AI Biomed PredictionsBNTC – Benitec’s next rerating likely hinges on FDA path clarity ScanScor Admin / May 20, 2026
AI Biomed PredictionsAUTL – Next Autolus rerating likely hinges on Q2 launch proof ScanScor Admin / May 20, 2026
AI Biomed PredictionsABEO – ZEVASKYN launch traction could force ABEO’s next sharp rerating ScanScor Admin / May 20, 2026
AI Biomed PredictionsNGNE – Mid-2026 Rett data could reignite Neurogene’s breakout case ScanScor Admin / May 12, 2026
AI Biomed PredictionsNGEN – NervGen’s next rerating likely hinges on 2Q clinical follow-through ScanScor Admin / May 10, 2026
AI Biomed PredictionsLRMR – June BLA filing could reset Larimar’s risk-reward profile ScanScor Admin / May 10, 2026
AI Biomed PredictionsAUTL – Autolus Faces Its First True Commercial Rerating Test ScanScor Admin / May 10, 2026
